Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.48 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 2/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5727061 | 0.75 | DHFR (0.46) | — | |
| SCHEMBL27648253 | 0.73 | PNP (0.61) | PNP | |
| Alcohol SCHEMBL28116206 | 0.73 | PNP (0.54) | PNP | |
| SCHEMBL28037851 | 0.72 | PNP (0.59) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL870861 | 0.69 | PI4KA (0.62) | PNPNUDT1PI4KAPI4K2BPI4K2A | |
| SCHEMBL10299367 | 0.69 | TLR7 (0.56) | TLR7 | |
| SCHEMBL2900522 | 0.68 | CDK1 (0.59) | NUDT1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2060080 | 0.67 | PDE4A (0.53) | PNPTLR7PDE4APDE4BPDE4C | |
| SCHEMBL2060210 | 0.67 | TLR7 (0.56) | TLR7NUDT1 | |
| SCHEMBL2060194 | 0.66 | TLR7 (0.55) | TLR7NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754728-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20060052403-A1 | Novel adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052403-A1 | Novel adenine compound and use thereof | ADORA1, P2RY10, HRH4 | PNP 1662/4885RNASEH1 1447/4885TLR7 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.